---
title: "Takeda forecasts FY2026 core revenue of ¥ 4,640 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294314791.md"
description: "Takeda Pharmaceutical maintained its FY2026 financial guidance, forecasting core revenue of JPY 4,640 billion, core operating profit of JPY 1,160 billion, and core EPS of JPY 472. In Q1, the company reported core revenue of JPY 1,219.9 billion and core operating profit of JPY 358.9 billion. Management stated that Q1 performance aligned with expectations, driven by resilient demand in core brands, which grew 2.3% at constant exchange rates, while new launches surged 22.6%."
datetime: "2026-07-30T06:49:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294314791.md)
  - [en](https://longbridge.com/en/news/294314791.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294314791.md)
generator: "portal-rs"
---

# Takeda forecasts FY2026 core revenue of ¥ 4,640 billion

-   Takeda kept its FY2026 forecast unchanged, targeting core revenue of JPY 4,640 billion, core operating profit of JPY 1,160 billion, core EPS of JPY 472. \* FY2026 Q1 core revenue totaled JPY 1,219.9 billion, with core operating profit of JPY 358.9 billion, core EPS of JPY 154. \* Management described Q1 performance as broadly in line with guidance, citing resilient demand across core in-line brands. \* Core in-line brands grew 2.3% at CER in Q1; new launches rose 22.6% at CER. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)

## Related News & Research

- [Takeda CHRO Nicola D. Greenway sells 12,980 ADS for $235,173.42](https://longbridge.com/en/news/296395853.md)
- [Takeda Pharmaceutical (NYSE:TAK) General Counsel Natalie Anne Marie Furney Sells 30,868 Shares of Stock](https://longbridge.com/en/news/295785108.md)
- [Coincheck Group N.V. GAAP EPS of ¥6.92, revenue of ¥114.33B](https://longbridge.com/en/news/296104610.md)
- [Takeda Pharmaceutical Insiders Sold Shares Worth Over $3.5M](https://longbridge.com/en/news/295731657.md)
- [Takeda Insiders Sold Shares Worth Over $3.2M](https://longbridge.com/en/news/295729897.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**